GeneLancet presented at 2023 26th ASGCT annual meeting. We reported the progress of our anti-HBV gene editing program (Poster # 511). CRISPR-Cas9/LgRNA eliminated ~99% of both HBsAg and HBeAg in single transfection in cell models. Also reported was our STAR editing data, which enabled precise gene editing. Utilizing endogenous cellular DNA-directed DNA polymerases, STAR editor is a two-component system comprising a Cas protein and a segRNA only.